CCAT - Certified Companion Animal Rehabilitation Therapist Pain Management and Pharmacology Questions and Answers

Question 1

A 12-year-old cat with stable chronic kidney disease (CKD) and painful osteoarthritis requires long-term analgesia. Which of the following medications should be avoided or used with extreme caution due to its potential to cause acute renal decompensation?

Accepted Answer

Meloxicam

Answer

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX) enzymes. These enzymes produce prostaglandins, some of which are crucial for maintaining adequate blood flow to the kidneys. In a cat with pre-existing CKD, inhibiting these protective prostaglandins can lead to reduced renal perfusion and acute worsening of kidney function. The FDA label for meloxicam carries a boxed warning regarding repeated use in cats due to risks of acute renal failure and death. While some studies have explored low-dose use in stable CKD cats under careful monitoring, it remains a drug that must be used with extreme caution in this population. The other options act on different pain pathways (calcium channels, opioid receptors, NMDA receptors) and are generally considered safer choices for analgesia in cats with CKD.

Question 2

Which of the following drug combinations best exemplifies the principle of multimodal analgesia for chronic, maladaptive pain by targeting both aberrant nerve signaling and central sensitization ('wind-up')?

Accepted Answer

Gabapentin and Amantadine

Answer

This combination effectively targets two key mechanisms of chronic pain. Gabapentin, a calcium channel modulator, is used to treat neuropathic pain by dampening aberrant nerve signals. Amantadine is an NMDA receptor antagonist that specifically targets and reduces central sensitization, or 'wind-up,' which is the amplification of pain signals in the central nervous system. Using them together addresses both peripheral and central components of maladaptive pain. Combining two NSAIDs (Carprofen/Meloxicam) or an NSAID and a steroid (Deracoxib/Prednisone) is contraindicated and dangerous. Combining two opioids (Tramadol/Buprenorphine) targets similar receptors and is not the best example of targeting distinct mechanisms for chronic pain.

Question 3

A canine patient with severe, chronic osteoarthritis pain that is poorly responsive to NSAIDs alone may be experiencing central sensitization. Which medication specifically targets the N-methyl-D-aspartate (NMDA) receptors to help manage this 'wind-up' pain?

Accepted Answer

Amantadine

Answer

Amantadine's primary role as an adjunctive analgesic is its function as an N-methyl-D-aspartate (NMDA) receptor antagonist. In states of chronic pain, NMDA receptors become over-activated, leading to an exaggerated pain response and central sensitization. By blocking these receptors, amantadine helps to reduce this 'wind-up' phenomenon. Galliprant is an EP4 receptor antagonist, Onsior is a COX-inhibiting NSAID, and Buprenorphine is a partial mu-opioid agonist.

Question 4

A 7-year-old Labrador with moderate hip osteoarthritis is managed with carprofen and a weight management plan. The owner wants to add a non-prescription supplement to support joint health. Which of the following nutraceuticals has the most clinical evidence, although sometimes conflicting, for providing chondroprotection and mild anti-inflammatory effects in canine osteoarthritis?

Accepted Answer

A combination of glucosamine, chondroitin sulfate, and ASU

Answer

While evidence for many nutraceuticals is still emerging, the combination of glucosamine, chondroitin sulfate, and often avocado/soybean unsaponifiables (ASU) has been the most extensively studied for canine osteoarthritis. These components are thought to provide cartilage building blocks (chondroprotection) and may exert mild anti-inflammatory effects. Although study results can be mixed, this combination is widely recommended by veterinarians. White willow bark contains salicylates and should be avoided with NSAIDs like carprofen.

Question 5

Galliprant (grapiprant) is a newer anti-inflammatory drug used for canine osteoarthritis that offers a different safety profile from traditional NSAIDs. What is its specific mechanism of action?

Accepted Answer

It antagonizes the EP4 receptor, a key prostaglandin E2 receptor for pain and inflammation.

Answer

Grapiprant is a piprant-class drug, not a traditional COX-inhibiting NSAID. It works downstream in the inflammatory cascade by selectively blocking the EP4 receptor. This is the primary receptor for prostaglandin E2 (PGE2) that mediates pain and inflammation associated with osteoarthritis. By targeting only this specific receptor, it avoids inhibiting the production of other prostaglandins that have important homeostatic functions in the GI tract, kidneys, and platelets, thus offering a different side-effect profile compared to traditional NSAIDs.

CCAT Practice Test

CCAT Practice Test

CCAT - Certified Companion Animal Rehabilitation Therapist Pain Management and Pharmacology Questions and Answers